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ABSTRACT
Background: Epidemiological evidence suggests that consumption
of cruciferous vegetables is associated with reduced risk of prostate
cancer progression, largely attributed to the biological activity of
glucosinolate degradation products, such as sulforaphane derived
from glucoraphanin. Because there are few therapeutic interventions
for men on active surveillance for prostate cancer to reduce the risk
of cancer progression, dietary approaches are an appealing option for
patients.
Objective: We evaluated whether consumption of a glucoraphanin-
rich broccoli soup for 1 y leads to changes in gene expression in
prostate tissue of men with localized prostate cancer.
Methods: Forty-nine men on active surveillance completed a 3-
arm parallel randomized double-blinded intervention study for 12
mo and underwent transperineal template biopsy procedures and
dietary assessment at the start and end of the study. Patients received
a weekly 300 mL portion of soup made from a standard broccoli
(control) or from 1 of 2 experimental broccoli genotypes with
enhanced concentrations of glucoraphanin, delivering 3 and 7 times
that of the control, respectively. Gene expression in tissues from
each patient obtained before and after the dietary intervention was
quantified by RNA sequencing followed by gene set enrichment
analyses.
Results: In the control arm, there were several hundred changes in
gene expression in nonneoplastic tissue during the 12 mo. These
were associated with an increase in expression of potentially onco-
genic pathways including inflammation processes and epithelial–
mesenchymal transition. Changes in gene expression and associated
oncogenic pathways were attenuated in men on the glucoraphanin-
rich broccoli soup in a dose-dependent manner. Although the
study was not powered to assess clinical progression, an inverse
association between consumption of cruciferous vegetables and
cancer progression was observed.
Conclusion: Consuming glucoraphanin-rich broccoli soup affected
gene expression in the prostate of men on active surveillance,
consistent with a reduction in the risk of cancer progression. This
trial was registered at clinicaltrials.gov as NCT01950143. Am J
Clin Nutr 2019;109:1133–1144.
Keywords: active surveillance, broccoli, dietary intervention,
transcriptome, RNA sequencing, SMCSO, sulforaphane, prostate
biopsy, cancer prevention
Introduction
The diagnosis of organ-confined prostate cancer has increased
owing to routine prostate specific antigen (PSA) testing and an
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ageing population. Up to 48% of cases may exhibit clinical
progression after subsequent examination, and a small proportion
of these may become metastatic with associated poor prognosis
(1, 2). However, owing to the risks associated with curative
treatment, men with organ-confined prostate cancer may choose
a program of “active surveillance,” in which radical treatment is
delayed until there is evidence of cancer progression. Currently,
there are no approved therapeutic interventions for men who have
chosen a program of active surveillance that may reduce the risk
of cancer progression.
Epidemiological studies have suggested a negative association
between consumption of cruciferous vegetables and incidence
or progression of prostate cancer (3–5). The protective activity
has been associated with the biological activity of degradation
products of glucosinolates, sulfur-containing glycosides that
accumulate in these vegetables. When consumed, glucosinolates
are degraded either due to the action of plant-derived thioglucosi-
dases or, if these have been denatured as a result of cooking,
by microbial activity in the colon (6). Glucosinolates with
aliphatic or aromatic side chains produce isothiocyanates, such as
sulforaphane derived from 4-methylsulphinylbutyl glucosinolate
(glucoraphanin) that accumulates in broccoli. Glucosinolates
with indole side chains produce indole-3-carbinol and associated
metabolites (Supplemental Figure 1A and B) (7). These
glucosinolate-derived metabolites exhibit a range of biological
activity in model systems consistent with the protective effects
of cruciferous vegetables (8). However, despite the large number
of studies with model systems, there are few examples of human
intervention studies with either biological or clinical endpoints
to provide further evidence that diets rich in glucosinolates,
glucoraphanin, or sulforaphane may prevent prostate cancer
progression. Cruciferous vegetables also accumulate S-methyl
cysteine sulfoxide (SMCSO) which, in an analogous manner
to glucosinolates, degrades to bioactive metabolites (9, 10)
(Supplemental Figure 1C).
We report a double-blinded randomized controlled trial to test
the hypothesis that a diet rich in glucoraphanin, the glycosylated
precursor of sulforaphane, would significantly modify gene
and metabolite expression in the prostate of men on active
surveillance for prostate cancer. We used broccoli genotypes
specifically developed to have enhanced concentrations of
glucoraphanin through the introgression of either 1 or 2 alleles
of theMyb28 transcription factor from the wild species Brassica
villosa but with otherwise identical chemical profiles (11, 12).
The primary outcome of the study was to detect changes in
gene expression in response to glucoraphanin-rich diets through
RNA sequencing from prostate biopsies, which were collected
at the start of the study and after the 12-mo intervention.
The secondary outcome was to analyze metabolites from these
biopsies.
We analyzed sequential transperineal template prostate biopsy
samples from prostate cancer patients immediately before (T0)
and after (T12) a 12-mo intervention with a broccoli soup
made from 1 of the 3 broccoli genotypes, and reported paired
analyses of global gene expression, gene set enrichment analyses
(GSEAs), and metabolite profiles (i.e., at T0 and T12) for each
of the volunteers. As several studies have reported interactions
between diet and Glutathione S-transferase mu1 (GSTM1)
genotype, we also investigated whether GSTM1 genotype may
affect the response to the dietary intervention. Finally, we
quantified the correlation between the intake of individual food
components and the clinical parameters of the patient cohort.
Methods
Ethics
The study (NCT01950143) was approved by the Quadram
Institute Bioscience Human Research Governance Committee
and by the National Research Ethics Service (Research Ethics
Committee ref: 13/EE/0110).
Study design
Effect of Sulforaphane on prostate CAncer PrEvention
(ESCAPE) was a randomized, double-blinded 3-arm parallel
intervention recruiting men aged 18–80 y with a BMI between
19.5 and 35 kg/m2. The men had a diagnosis of low-risk prostate
cancer (PSA < 10 ng/mL, Gleason grade 6; T category T1 or
T2) or intermediate-risk prostate cancer (PSA 10–20 ng/mL,
Gleason 7, including selected 4 + 3 cases that made informed
decisions against radical treatment; T category T1 or T2) and
were undergoing active surveillance. Complete eligibility and
exclusion criteria are detailed in Supplemental Table 1. The
primary outcome was gene expression of prostate tissue obtained
before and after a dietary intervention and the secondary outcome
was changes in metabolites. The study was powered based upon
data obtained from a previous pilot study (13). The number of
volunteers necessary to report statistically significant changes in
gene expression was calculated by 2 methods: firstly, by using
the “Sample Size for Microarray Experiments” tool developed
by the Section of Bioinformatics of the University of Texas MD
Anderson Cancer Center (https://biostatistics.mdanderson.org/M
icroarraySampleSize/); and secondly, by reported calculations
based on previously published data (14). We estimated that
26 subjects in each of the 3 dietary groups (78 in total)
were required to detect 1.5-fold differences with a significant
difference (P< 0.02) between any 2 of the 3 dietary groups, with
a power of 80% and an SD of 0.66 (based on a log2 scale of gene
intensity measurements). However, the accrual rate was below
that anticipated and recruitment was stopped before reaching the
target sample size goal in order to complete the study within
the scheduled date of closure (October, 2016). Patients (n = 61)
were recruited through the Urology Department of the Norfolk
and Norwich University Hospitals NHS Foundation Trust from
October, 2013 to October, 2015.
Study patients were randomly allocated to 1 of 3 dietary
arms in which they were required to consume 1 portion of
broccoli soup (300 mL) per week as part of their normal diet
for 12 mo, with an option to continue the intervention for a
further 12 mo. For an optional extension (12–24 mo), patients
underwent regular blood analyses, as described below, but no
additional study biopsies were collected. Block randomization
(www.randomization.com) and blinding were performed by an
individual who was not part of the study team. The soups were
manufactured by Bakkavor from the commercial cultivar Iron
(soup X, genotype Myb28 B/B), the cultivar Beneforte (soup
Y, Myb28 B/V, in which V represents an introgressed Myb28
allele from B. villosa), or a noncommercial hybrid cultivar
(soup Z,Myb28V/V). Three-hundred-milliliter portions of soups
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manufactured from these 3 genotypes contained 72 ± 2.8
(soup X), 214 ± 7.3 (soup Y), and 492 ± 3.2 (soup Z)
μmol 4-methylsulphinylbutyl glucosinolate (glucoraphanin). A
previous study reported that these different soup products resulted
in contrasting concentrations of sulforaphane in the systemic
circulation (12). One weekly portion of soup X was assigned
as the control arm, because this soup was manufactured from a
commercial cultivar of broccoli and could be expected to be part
of a normal diet. This soup provided the lowest concentration of
glucoraphanin, which, and on the basis of epidemiological studies
(3), would be considered beneath the threshold required for a
reduction in cancer progression.
Patients underwent 2 transperineal template biopsy (TTB)
procedures, 1 at the start of the intervention (T0) and 1 after
12 mo (T12). Of the 24–56 TTB cores per patient obtained at
each TTB, several were individually reserved either in RNAlater
for RNA sequencing or in extraction solvent (80% HPLC grade
methanol:20% water) for targeted and nontargeted metabolite
analyses. Two further cores were snap frozen, and the remainder
underwent routine histopathological examination. The tissue was
examined by a single consultant histopathologist with a special
interest in prostate pathology to reduce interobserver error, a
potential hazard in diagnosing and grading prostate cancer (15).
After histopathology, cores were selected for RNA sequencing
analyses that were adjacent to cores that did not contain cancer.
Dietary analyses
Patients completed a comprehensive 7-d diet diary imme-
diately before the study to assess their habitual diet, and
subsequently at 6 and 12 mo. Diet data were analyzed through
DietPlan6 (Forestfield Software Ltd, UK) and combined with
additional data on the chemical composition of cruciferous
and alliaceous vegetables, obtained from analyses of vegetables
purchased in retail outlets in the localities of the volunteers, as
previously described (16).
Gene expression analyses by RNA sequencing
The primary outcome of the study was to detect changes in
gene expression in response to the dietary intervention through
RNA sequencing, from prostate biopsies collected at the start of
the study and at 12 mo, i.e., after the intervention. Histology of
the directly adjacent region confirmed that the prostate biopsies
used for RNA sequencing were unlikely to contain neoplastic
tissue. Cores of between 3 and 10 mg from each patient
were homogenized with a QIAGEN TissueRuptor before total
RNA was extracted with the QIAGEN RNeasy Mini kit. The
resulting RNA was quality checked with an Agilent Bioanalyzer
and samples with RIN values >7 were further processed.
Samples were ribodepleted with the Ribo-Zero Magnetic Gold
rRNA Removal Kit (Illumina) before constructing Illumina
barcoded TruSeq RNA libraries. Sequencing of 98 libraries
was performed on an Illumina HiSeq 2500/2000 in high-output
mode using 125-bp paired-end reads, generating 50–70 million
reads/library. RNA-seq reads were first processed by removing
Illumina adapters using Trim Galore! version 0.4.2 (Babraham
Bioinformatics) and reads with Phred quality of basecalls >20
and with a length of >60 bp were carried forward. SortMeRNA
version 2.1 (17) was used to filter any remaining ribosomal RNA
from the adaptor and quality trimmed reads.
Reads were analyzed using theHISAT2-StringTie pipeline (18)
aligned to the Ensembl GRCh38.89 reference genome (HISAT2
version 2.0.5 and StringTie version 1.3.3), and gene counts were
exported into edgeR in R Bioconductor (19). One patient was
removed from all analyses because he underwent prostatectomy
at 12 mo, rather than TTB, leaving a total of 48 patients (96
libraries). The complete bioinformatics pipeline, differential gene
expression (DGE) analyses, and statistical analysis are available
as a GitHub repository (https://github.com/quadram-institute-bio
science/ESCAPE_RNAseq_analysis).
In addition, we conducted a query on publicly available RNA
sequencing data that were generated using the same Illumina
HiSeq 2000/2500 technology as our samples, had ≥100-bp
paired reads, and contained benign as well as primary cancer
samples. We identified accession GSE80609 in Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo) and downloaded
the raw reads (.fastq) before analyzing them with the same
pipeline as our samples, described above. When ESCAPE and
GSE80609 samples were put together in edgeR we generated
multidimensional scaling (MDS) plots for the second and
third dimensions, because the first dimension was clearly only
differentiating the 2 separate studies (data not shown).
RNA sequencing data from the ESCAPE study have been
deposited in ArrayExpress (accession E-MTAB-6525).
Metabolomics analyses
Desiccated methanol extracts, derived from 24-h incubation
of 1 prostate biopsy per patient, were sent to Metabolon
Inc. to undergo ultra-HPLC–mass spectroscopy (MS) and gas
chromatography–MS with a high resolution accurate mass
(HRAM) platform as previously described (20) (www.metabolo
n.com). A total of 448 metabolites were semiquantified on the
basis of ion count within several biologically relevant classes
(amino acids, carbohydrates, vitamins, lipids, nucleotides, pep-
tides, tricarboxylic acid cycle, and xenobiotics). Histology of the
core after incubation confirmed the absence of cancerous foci.
Blood analyses
Biomarkers of liver and kidney function and full blood count
were quantified at T0 and T12 to ensure the glucoraphanin-rich
soup had no toxic effects. Fasting blood glucose, PSA, and serum
lipid profile (cholesterol, HDL cholesterol, LDL cholesterol,
triglyceride) were quantified at 3-mo intervals, up to 24 mo
from the start of the study. GSTM1 genotype was quantified as
previously described (13).
Statistical analyses
Analyses of clinical characteristics.
The difference between clinical parameters (age, BMI, PSA)
between the 3 different groups at the start and at the end of
the study was assessed either by using ANOVA and correcting
for multiple testing by Tukey’s multiple correction test, or by
Kruskal–Wallis test corrected for multiple testing by Dunn’s,
where appropriate.
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DGE analyses.
Paired DGE analysis after calculation of normalized gene
counts was undertaken in limma after voom transformation
(21). Adjustment for multiple testing was performed using the
Benjamini–Hochberg false discovery rate (FDR) method. MDS
plots generated in EdgeR were used to determine the variation
within different groups at the start and the end of the study.
Statistical significance of unadjusted and FDR-adjusted P values
was reported for different thresholds.
Functional analyses.
Functional analyses of paired DGE were undertaken by the
GSEA software (22) using the Hallmark gene sets (50 gene
sets in total) within the available Molecular Signatures Database
(MSigDB, version 6.1). DGE lists were ranked according to their
P value, modified using the rank–rank hypergeometric overlap
(RRHO) algorithm (23). Modified P values were calculated as
the signed log10-transformed P value of the paired log fold
change over 12 mo for each dietary arm, with the sign denoting
the direction of the change: positive for upregulated over time,
and negative for downregulated over time. By using the RRHO
method we explored the functional consequences of the paired
changes in gene expression without being constrained by a given
statistical threshold. The ranked DGE list was then submitted
to GSEA and statistical significance of enriched pathways was
set at an FDR-adjusted P value <0.05. Normalized enrichment
scores for each individual pathway and their associated FDR-
adjusted P value for each diet were reported with and without
stratification by GSTM1 genotype. An MDS plot was generated
in EdgeR to determine the variation in normalized enrichment
scores for the different dietary groups stratified by GSTM1
genotype.
Metabolomics analyses.
Paired Student’s t tests were undertaken for each individual
metabolite within each dietary arm. Adjustment for multiple
testing was performed using the Benjamini–Hochberg FDR
method. Comparisons of log2-fold changes for each metabolite
between dietary arms were made by unpaired t tests with FDR
correction.
Exploratory association with clinical outcomes.
Individual dietary components, calculated from the diet diaries
of the patients reported at the start and the end of the study,
were tested for association with histological and blood markers.
This exploratory analysis was undertaken in the R environment
(R Foundation) using Pearson correlations. Gleason scores were
adjusted to be no lower than any previous biopsy, to correct for
the undetected cancers in this cohort, and subsequently were con-
verted to risk groups according to the WHO grade group system
(24), to allow differentiation between Gleason 7 scores (3 + 4
or 4 + 3), which occupy different grade groups under the WHO
system.
Results
Clinical characteristics and dietary assessment of subjects
Sixty-one men on active surveillance were randomly assigned
to 1 of the 3 dietary intervention arms and 49 completed the
study (Figure 1). Of the 12 volunteers who did not complete
the study, 5 exhibited clinical progression before the start of the
dietary intervention after their first TTB, 4 withdrew consent
during the study for unknown reasons, and 3 did not undergo a
second TTB for either clinical or personal reasons. There were
no significant differences in age, BMI, frequency of GSTM1 null
genotypes, or PSA between the 3 groups at the start or the end of
the study (Table 1). Similarly, there were no significant changes
in biomarkers of kidney and liver function and metabolism over
time or differences between the 3 arms of the study, during the
12-mo study (Table 1; Supplemental Table 2). Fasting blood
glucose concentrations showed an initial fall over the first 6
mo of the study, and then a further fall between 12 and 18 mo
(Supplemental Figure 2).
At baseline, there were no differences in the habitual diet
of the volunteers between the 3 arms, and there were no
changes during the 12-mo intervention period with the exception
of glucoraphanin intake which, as expected, was significantly
different between the 3 arms owing to the provision of the
broccoli soups (Supplemental Table 3).
Gene expression profiles of nonneoplastic prostate biopsies
We first compared the transcriptional prostate signature of
our cohort with that from a previous study that compared
transcriptional profiles from benign prostate hyperplasia and
primary prostate cancer (25). Apparent nonneoplastic biopsies
from the ESCAPE patients were intermediate between the BPH
samples and the prostate cancer samples, although with some
overlap with the cancer samples (Figure 2). This indicates
that transcriptional changes may be occurring across the whole
prostate of patients on active surveillance, with some similarities
with those occurring in the cancer lesions themselves, consistent
with a “field effect.”
In order to determine whether the transcriptional profiles of
the 3 groups at the start or the end of the study differed despite
the random group assignment, we used MDS plots to assess
variability and found no evidence of outliers, either in single
patients or in diet groups (Supplemental Figure 3A and B).
Paired DGE analyses and GSEAs
We investigated the changes in gene expression that occurred
within each arm over time. In the control group (i.e., those
that received a single portion of broccoli soup made from
standard broccoli, genotype Myb28 B/B, soup X) we found
significant changes in gene transcription (FDR-adjusted P< 0.1,
Table 2).
GSEA, with the use of the RRHO method that takes into
account all the genes ranked by P value and fold change,
identified significant enrichment of pathways associated with
the risk of carcinogenesis (FDR-adjusted P < 0.05, Table 3),
including inflammatory response (Supplemental Figure 4) and
epithelial–mesenchymal transition (Supplemental Figure 5).
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FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patients on surveillance receiving 1 of the 3 dietary interventions
over 12 mo and the schedule of biopsies and analyses. PSA, prostate-specific antigen; TPB, trans perineal biopsy.
Among the significantly enriched pathways were also those
associated with androgen response (FDR-adjusted P < 0.001),
angiogenesis (FDR-adjusted P < 0.001), and apoptosis (FDR-
adjusted P < 0.002; Table 3).
When the intake of glucoraphanin was enhanced through the
use of broccoli soup with genotype Myb28 V/B (soup Y) or
genotype Myb28 V/V (soup Z), the extent of change in gene
expression over time was suppressed, even at a low statistical
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TABLE 1 Patient characteristics1
Soup X (control; low
GR)
Soup Y (intermediate
GR) Soup Z (high GR)
n 15 17 16
n of GSTM1 (−/−) 9 10 12
Age,2 y 68 ± 5 66 ± 6 66 ± 6
BMI,2 kg/m2 26.7 ± 3.1 27.6 ± 3.4 27.7 ± 2.2
Days from initial diagnosis2 309 ± 232 312 ± 356 327 ± 292
At diagnosis
PSA, μg/L3,4 7.7 (5.9–7.9) 6.8 (5.6–8.6) 7 (5.0–9.3)
Gleason score,5 n
3 + 3 10 10 9
3 + 4 4 5 6
4 + 3 1 2 0
At 0 mo
PSA, μg/L3 7.9 (5.9–12.0) 7.6 (4.9–9.4) 5.8 (4.4–8.7)
PSA density3 0.10 (0.08–0.18) 0.13 (0.09–0.18) 0.10 (0.08–0.16)
Gleason score
3 + 3 5 7 1
3 + 4 7 5 10
4 + 3 0 0 0
Undetected 3 5 5
Core ratio3 7.9 (3.0–14.3) 3.7 (0–9.4) 11.6 (0–16.1)
At 12 mo
PSA, μg/L3 9.4 (6.6–10.4) 7.3 (6.9–10.4) 7.5 (5.6–9.3)
PSA density3 0.13 (0.10–0.02) 0.12 (0.08–0.17) 0.11 (0.08–0.14)
Gleason score
3 + 3 2 5 2
3 + 4 9 4 10
4 + 3 0 1 3
4 + 4 1 0 0
Undetected 3 7 1
Core ratio3 7.7 (4.2–21.7) 4.4 (0–16.6) 13 (6.4–17.5)
1GR, glucoraphanin; GSTM1, Glutathione S-transferase M1; PSA, prostate specific antigen.
2Nonsignificant difference (i.e., all P values >0.5) between diets as determined by ANOVA adjusted by Tukey’s multiple correction test. Data shown are
mean ± SD.
3Nonsignificant difference (i.e., all P values >0.2) between diets as determined from the Kruskal–Wallis test adjusted by Dunn’s multiple correction test.
Data shown are median (IQR).
4PSA at diagnosis missing for 3 patients on Diet X, 1 on Diet Y, and 1 on Diet Z.
5Gleason score at diagnosis missing for 1 patient on Diet Z.
threshold (Figure 3). Interestingly, men who consumed the
highest amount of glucoraphanin (soup Z) had only 1 gene
that significantly changed in expression over the 12-mo period
(FDR-adjusted P < 0.5), in contrast to the multiple changes in
the control arm (soup X) or the more modest changes in the
intermediate glucoraphanin arm (soup Y; Table 2, Figure 3).
In the same manner as we did for the control arm, we explored
the functional pathways enriched by soups Y and Z. GSEAs
for soup Y were largely similar to those of the control soup.
However, soup Z contrasted markedly with the control soup, by
a lack of significant enrichment for the majority of pathways,
including inflammatory response and epithelial–mesenchymal
transition (Table 3).Moreover, in contrast to control soupX, there
was significant enrichment of downregulated genes for reactive
oxygen species and xenobiotic metabolism pathways by soup Z
(Table 3).
Analyses with GSTM1 stratification
Analyses of the paired gene expression in the 3 dietary arms
stratified by GSTM1 null and non-nulls suggested that within
intervention arms receiving soups X and Y the changes in gene
expression were restricted to GSTM1 non nulls (FDR-adjusted
P < 0.1, Supplemental Table 4). GSEAs for the GSTM1 nulls
and non nulls were very similar in soup X, in terms of direction
and magnitude of change of pathways, but exhibited some
divergence in soups Y and Z indicative of a possible diet–gene
interaction (Supplemental Table 5, Supplemental Figure 6).
Effect of intervention on nuclear factor (erythroid-derived
2)-like 2–regulated genes
Sulforaphane, which would have been derived from the gluco-
raphanin delivered by the 3 different soups, is a potent inducer
of nuclear factor (erythroid-derived 2)-like 2 (NRF2)-regulated
genes. We therefore extracted from the RNA sequencing data
the expression of previously defined NRF2-target genes (26)
(Supplemental Table 6). There was no evidence of a change
in expression of any NRF2-regulated genes between the start
and end of the dietary intervention (Benjamini–Hochberg FDR-
adjusted P value <0.1).
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FIGURE 2 Multidimensional scaling plot of the ESCAPE cohort
prostate biopsies (ESC) alongside publicly available (GSE80609) BPH and
CaP samples. BPH, benign prostatic hyperplasia; CaP, primary prostate
cancer; ESCAPE, Effect of Sulforaphane on prostate CAncer PrEvention; FC,
fold change.
Metabolomics analyses
Paired analyses of metabolites from tissue biopsies did not
identify any significant changes in metabolites within any of
the 3 dietary intervention arms. There was also no evidence for
differences in fold changes in metabolites between dietary arms
(data not shown).
Exploratory analysis with clinical parameters of prostate
cancer progression
Ten out of 48 patients (28%) exhibited an increase in their
cancer grade over the 12 mo of the study. Although our study
was not powered to assess a clinical endpoint of prostate cancer
progression, we undertook exploratory analysis and observed
that the dietary intake of cruciferous vegetables at the start of
the study (T0) was significantly inversely correlated with the
change in WHO grade over the 12-mo study period (Figure 4A).
This association was still apparent at T12, but not significant at
P< 0.05 (data not shown). When we averaged the dietary intakes
over 12 mo, the most significant inverse relation was between
consumption of SMCSO and increase inWHOgrade (Figure 4B).
Discussion
The primary aim of the study was to test the hypothesis that
enhancing glucoraphanin in the diet would result in changes in
gene expression in prostate tissue of men on active surveillance
that are consistent with reduction in the risk of cancer incidence
or progression.
One of the challenges in seeking evidence for the protective
effects of dietary components within a complex food matrix
is experimental design. To test the effect of glucoraphanin
within broccoli, we used 3 broccoli genotypes with contrasting
glucoraphanin contents due to their Myb28 genotype, enabling a
randomized double-blinded dietary intervention study.
We analyzed changes in gene expression from sequential
prostate tissue biopsies of the same individuals and found that
in the control/placebo arm (i.e., commercially available broccoli)
several hundred changes in gene expression occurred within the
12-mo period (Table 2, Figure 3). Subsequent GSEA indicated
that the tissue within the control arm was likely to be at risk of
carcinogenesis, with increased expression of several pathways
associated with carcinogenesis or cancer progression (Table 3).
It is notable that these changes may have been occurring in tissue
that was histologically normal, consistent with a “field effect” in
the prostate gland, and with studies of whole-genome sequencing
of noncancerous prostate tissue (27). The amount of broccoli or
glucoraphanin consumed by men in this control arm was below
the threshold that has been reported in epidemiological studies to
reduce the risk of cancer progression (3), and, likewise, there is
no reason to suggest that the low amount of glucoraphanin would
have induced these changes.
The changes in gene expression observed in the control dietary
arm were suppressed by the diets with soups with enhanced
glucoraphanin, in a dose-dependent manner. Thus, consuming
soup Y (Myb28 B/V), delivering intermediate amounts of
glucoraphanin, resulted in fewer changes in gene expression,
whereas consuming soup Z (Myb28 V/V), delivering the highest
amounts of glucoraphanin, entirely suppressed changes in gene
expression seen in the control arm (Table 2, Figure 3). Moreover,
GSEA functional pathway analyses of Soup Z were markedly
different to those of Soup X (Table 3).
TABLE 2 Number of genes changed over time with the different diets1
Soup X (n = 15) (control;
low GR)
Soup Y (n = 17)
(intermediate GR) Soup Z (n = 16) (high GR)
FDR-adjusted P value2
<0.05 7 (4↑, 3↓) 0 0
<0.1 96 (58↑, 38↓) 0 0
P value3
<0.001 154 (82↑, 72↓) 26 (20↑, 6↓) 12 (8↑, 4↓)
<0.01 980 (520↑, 460↓) 331 (224↑, 107↓) 83 (46↑, 37↓)
<0.05 2796 (1460↑, 1336↓) 1359 (783↑, 576↓) 502 (277↑, 225↓)
1FDR, false discovery rate; GR, glucoraphanin. ↑ indicate increase in gene expression. ↓ indicate decrease in gene expression.
2Paired t tests, adjusted for multiple testing correction by Benjamini–Hochberg.
3Student’s paired t tests, unadjusted for multiple testing correction.
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TABLE 3 GSEA of paired changes over time for the control arm (soup X, low GR) and the experimental arms (soup Y, intermediate GR; soup Z, high GR)1
Soup X (control; low GR) Soup Y (intermediate GR) Soup Z (high GR)
MSigDb pathway SIZE NES FDR P value2 NES FDR P value2 NES FDR P value2
TNFA signaling via NFKB 167 2.653 0 3 2.89 3 0 3 − 1.33 0.121
Epithelial–mesenchymal transition 176 2.70 3 0 3 2.30 3 0 3 − 1.03 0.558
Hypoxia 164 1.95 3 0 3 1.88 3 0 3 − 0.97 0.655
Inflammatory response 152 1.95 3 0 3 2.36 3 0 3 0.95 1
TGF β signaling 46 2.03 3 0 3 1.58 3 0.007 3 0.82 1
Protein secretion 91 − 1.99 3 0 3 − 1.56 3 0.012 3 − 1.36 0.095
Androgen response 93 − 2.13 3 0 3 − 1.62 3 0.014 3 − 1.45 0.055
Myogenesis 173 2.01 3 0 3 1.51 3 0.018 3 − 2.30 3 0 3
UV response DN 133 2.11 3 0 3 1.29 0.090 − 0.77 0.953
Angiogenesis 30 1.89 3 0.001 3 2.06 3 0 3 − 1.61 3 0.016 3
IL2 STAT5 signaling 154 1.84 3 0.001 3 2.21 3 0 3 − 1.25 0.191
Coagulation 89 1.76 3 0.001 3 2.08 3 0 3 − 0.85 0.924
Interferon-γ response 162 1.81 3 0.001 3 2.47 3 0 3 0.77 0.931
KRAS signaling UP 157 1.81 3 0.001 3 1.88 3 0 3 − 0.81 0.957
Apoptosis 140 1.71 3 0.002 3 1.99 3 0 3 − 1.19 0.259
Notch signaling 29 1.68 3 0.003 3 1.08 0.344 1.10 0.851
Fatty acid metabolism 127 − 1.76 3 0.003 3 0.88 0.765 − 1.64 3 0.016 3
IL6 JAK STAT3 signaling 61 1.63 3 0.004 3 2.13 3 0 3 − 0.66 0.989
Unfolded protein response 98 − 1.68 3 0.004 3 1.49 3 0.020 3 − 1.58 3 0.018 3
Cholesterol homeostasis 63 − 1.72 3 0.004 3 0.73 0.956 − 1.43 0.062
Apical junction 163 1.60 3 0.005 3 2.04 3 0 3 − 1.23 0.206
Peroxisome 82 − 1.63 3 0.008 3 0.99 0.504 − 1.02 0.567
Complement 144 1.44 3 0.025 3 1.96 3 0 3 0.97 1
Mitotic spindle 171 1.44 3 0.025 3 1.23 0.150 1.24 0.482
P53 pathway 171 1.41 3 0.033 3 2.05 3 0 3 − 0.97 0.665
Allograft rejection 146 1.39 3 0.035 3 2.13 3 0 3 1.28 0.697
MYC targets V1 178 − 1.44 0.051 1.48 3 0.021 3 − 2.11 3 0 3
MTORC1 signaling 179 − 1.42 0.054 1.35 0.066 − 1.50 3 0.039 3
Interferon-α response 81 1.27 0.091 2.00 3 0 − 0.78 0.974
Estrogen response early 167 1.19 0.159 1.99 3 0 − 1.24 0.202
DNA repair 117 − 1.26 0.187 1.40 3 0.044 3 − 1.13 0.355
Hedgehog signaling 30 1.11 0.260 1.66 3 0.003 3 − 0.95 0.651
UV response UP 128 1.10 0.266 1.73 3 0.001 3 − 1.71 3 0.009 3
Reactive oxygen species 42 − 1.14 0.302 1.32 0.077 − 1.63 3 0.014 3
MYC targets V2 51 − 1.14 0.323 1.82 3 0 3 − 1.71 3 0.011 3
Xenobiotic metabolism 139 − 1.09 0.356 1.48 3 0.020 3 − 1.65 3 0.016 3
Oxidative phosphorylation 174 − 1.08 0.366 0.79 0.907 − 2.16 3 0 3
Estrogen response late 162 − 1.01 0.505 1.88 3 0 3 − 1.28 0.163
Adipogenesis 164 − 0.93 0.736 1.10 0.328 − 1.86 3 0.0023
E2F targets 147 − 0.86 0.828 1.42 3 0.036 3 0.93 1
1FDR, false discovery rate [as described in (22)]; E2F, E2 Factor; GR, glucoraphanin; GSEA, gene set enrichment analysis; IL6, interleukin 6; JAK,
Janus Kinase; KRAS, V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog; MSigDb, Molecular Signature Database; MTORC1, mammalian target of
rapamycin complex 1; MYC, myelocytomatosis; NES, normalized enrichment score; NFKB, nuclear factor kappa B1; STAT, signal transducer and activator
of transcription; TGF, transforming growth factor; TNFA, tumor necrosis factor a; UV, ultra violet. SIZE refers to the numbers of genes in the pathway. UV
response DN refers to genes that are down regulated by UV radiation. UV response UP refers to genes that are up regulated by UV radiation.
2GSEA by GSEA software version 3.0 on all genes ranked by the significance of fold change (see Methods section for details;
http://software.broadinstitute.org/gsea).
3Only pathways significant at FDR-adjusted P < 0.05 in ≥1 of the 3 diets are shown.
Meta-analyses of epidemiological studies have associated the
GSTM1 null genotype with enhanced risk of prostate cancer (28,
29) and cancer at other sites (30–32), and several epidemiological
studies have reported that the beneficial effect of diets rich
in cruciferous vegetables in reducing cancer risk is modified
by GSTM1 genotype (33–37). Experimental human dietary
intake studies with biological markers have reported greater
effect of isothiocyanate intake with GSTM1 null individuals
than those with 1 or 2 GSTM1 alleles (38, 39). We undertook
exploratory analyses of the possible interaction between GSTM1
genotype and diet by stratifying each arm by genotype and
analyzed the changes in paired gene expression and GSEA.
We found that changes in gene expression only occurred in
GSTM1 non null individuals. One explanation is that, as with
previous studies (38, 39), GSTM1 null individuals had a greater
response to sulforaphane and thus even with the low-dose
glucoraphanin diet there was some attenuation of changes in
gene expression. However, after GSEA, enrichment scores of
pathways were similar in both GSTM1 genotypes on the control
diet (Soup X; Supplemental Figure 6), indicating that if there
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FIGURE 3 Volcano plots of differentially expressed genes over time. Highlighted are the genes that are significantly upregulated or downregulated over
time in each dietary arm, colored in red or blue, respectively. Even at a low statistical threshold we do not observe any changes in gene expression with the
high-glucoraphanin soup (Soup Z) (false discovery rate–adjusted P value <0.5, paired t tests adjusted by Benjamini–Hochberg for multiple testing correction).
adjP refers to a probability value that has been adjusted for multiple testing with the use of Benjamini-Hochberg false discovery rate method.
was any effect of glucoraphanin on gene expression it was
insufficient to attenuate oncogenic pathways. Similar results
were found after consumption of soups Y and Z, albeit with
some indication of an increasing divergence of enrichment of
pathways between GSTM1 genotypes with increasing gluco-
raphanin content of diet, indicative of a possible diet × gene
interaction.
Based upon results from cell and animal model systems we
expected an intervention with glucoraphanin (and hence sul-
foraphane) would induce gene expression in a manner that would
reduce the risk of cancer incidence or progression. In contrast,
we observed a suppression of changes in gene expression. This
finding was only apparent owing to our innovative experimental
design, and would not have been evident if we had just compared
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FIGURE 4 Analysis of dietary components. (A) Correlation matrix
of the change in blood and histological markers over 12 mo, and the
baseline concentrations of cruciferous vegetables and sulfur-metabolites. (B)
Correlation matrix of the change in blood and histological markers over
12 mo, and the mean concentrations of cruciferous vegetables and sulfur-
metabolites over the same period. Color denotes the direction of the Pearson
correlation and dot size denotes the significance; only significant correlations
(P < 0.05) are shown; numbers denote the Pearson correlation. ITC,
isothiocyanate; PSA, prostate specific antigen; SMCSO, S-methyl cysteine
sulfoxide. adjWHO grade refers to a WHO grade that has been adjusted to be
no lower than that recorded from a previous biopsy, as described in materials
and methods.
individuals at a single time point (e.g., 12 mo). There are
few reports of sequential global gene expression in model
systems. One example is the suppression of changes in gene
expression (“transcriptional drift”) by the antidepressantmiaserin
in Caenorhabditis elegans (40, 41), in a somewhat analogous
manner to the attenuation of changes in gene expression that was
observed with the high-glucoraphanin soups. Moreover, miaserin
attenuated an oxidative transcriptional signature (41), and this
modulation of redox status was considered to be associated with
the reduced transcriptional drift associated with ageing of C.
elegans. This is analogous to the significant reduction in the
enrichment score of the reactive oxygen species pathway induced
by the high-glucoraphanin soup (Table 3). It is well established
that sulforaphane derived from glucoraphanin induces acute
oxidative stress followed by induction of NRF2-regulated genes
that modulate cellular redox status (8). In our study, we did
not observe any changes in expression of NRF2-regulated genes
(Supplemental Table 6). This may be due to the transient nature
of the changes in the expression of these genes, with changes only
occurring in the few hours directly after consuming the soup.
However, the regular (once-weekly) exposure to sulforaphane
in the high-glucoraphanin intervention arm may result in the
maintenance or improvement of redox status of the prostate
tissue that inhibits the changes in gene expression associated
with oncogenic pathways that were observed in the control
arm.
These data suggest that the putative chemopreventive effects
of a diet rich in cruciferous vegetables and glucoraphanin are not
mediated by direct effects upon cancerous clones, but through a
more generic “antiaging” effect. This would be consistent with
the beneficial effect of a diet rich in cruciferous vegetables on
other chronic age-related diseases (42, 43). Alternatively, the
effects of our intervention could be through epigenetic regulation
(44). Broccoli sprouts and sulforaphane have been shown to
reduce prostate cancer incidence through reduction of histone
deacetylation 3 (HDAC3) in mice, and altering global DNA
methylation in prostate cell models (45, 46). Despite these
speculations, there is clearly a “mechanistic gap” between the
phenomena observed in model systems, that often involve short-
term high-dose exposures, and those observed in human studies
for which there are several ethical and clinical constraints in
study design. This may be partially resolved through improved
experimental design in model systems that use longer and lower-
dose interventions and sequential analyses of tissues, and more
innovative human studies involving analyses of biopsy tissues
after precisely timed dietary interventions.
One of the limitations of our trial was the relatively small
sample size, resulting from the low accrual rate of eligible
patients, and we did not meet our target recruitment to achieve
the original power estimation. Having fewer patients in each
arm may have decreased the number of genes identified as
being differentially expressed at a fixed FDR-adjusted P value
and moderated the GSEA, but each arm would have been
affected equally and it is not likely that under-recruitment
could explain the differences between groups that we observed.
Obtaining and analyzing sequential paired prostate biopsy
samples from the patients rendered our data less susceptible
to interindividual variability, thus partly compensating for the
reduced sample size. Another limitation was that the biopsies
analyzed were all considered nonneoplastic, based on directly
adjacent histology. Although this assumption may be erroneous
for some of the biopsies, the global transcriptional profiles of
all the biopsies within our cohort were more similar to the
profiles of primary prostate cancer, suggesting that the whole
prostate undergoes transcriptional changes at the onset of prostate
cancer.
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In conclusion, our data are entirely consistent with epidemi-
ological studies that inversely correlate diets rich in either
cruciferous vegetables or glucosinolates with prostate cancer
incidence or progression. We report that an intervention rich in
glucoraphanin attenuated the transcriptional changes occurring
in prostate of men on active surveillance over a period of 12
mo. Although our study was not designed or sufficiently powered
to quantify clinical endpoints, we also observed a negative
correlation between the intake of cruciferous vegetables and
their associated sulfur-metabolites, and the change in WHO
grade over time (Figure 4). Further studies are warranted to
explore this association, with sufficient volunteer numbers and
appropriate follow-up time to assess clinical endpoints in an
active surveillance cohort. The results of the study would support
a public health recommendation to include cruciferous vegetables
as part of the diet to maintain and promote health.
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